HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (1- methyl- 5- indolyl)- N'- (3- methyl- 5- isothiazolyl)urea

a 5-HT(2B) receptor antagonist; structure given in first source

Also Known As:

MIMIU; SB204741

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: 7
Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: 7

Experts

1.	Kaji, Takao: 1 article (12/2020)
2.	Nonogaki, Katsunori: 1 article (12/2020)
3.	Huo, Fu-Quan: 1 article (01/2020)
4.	Jia, Hong: 1 article (01/2020)
5.	Liu, Hua: 1 article (01/2020)
6.	Tang, Jing-Shi: 1 article (01/2020)
7.	Wang, Yu-Ying: 1 article (01/2020)
8.	Xu, Wen-Jin: 1 article (01/2020)
9.	Zhao, Yan: 1 article (01/2020)
10.	Agarwal, Vikas: 1 article (12/2018)

Related Diseases

1.	Fibrosis (Cirrhosis) 01/01/2015 - "Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heart function in mice after PAB. " 12/01/2018 - "Terguride and SB204741 reduce pro-fibrotic potential of HADF cells and suppress TGF-β1-mediated non-canonical pathways, ERK1/2 and STAT3 which have been implicated in the regulation of pro-fibrotic genes and in the development of fibrosis. "
2.	Neoplasms (Cancer) 01/01/2017 - "Administration of SB204741 to KPC mice slowed growth and metabolism of established pancreatic tumors and prolonged survival of the mice. " 01/01/2017 - "Primary PDACs, with or without exposure to SB204741 (a selective antagonist of HTR2B), were grown as xenograft tumors in mice, and SB204741 was administered to tumor-bearing KPC mice; tumor growth and metabolism were measured by imaging analyses. " 04/01/2009 - "SB204741 reduced microvessel density in tumors and inhibited the proliferation of HUVEC in vitro. "
3.	Hypotension (Low Blood Pressure) 01/01/2000 - "BW723C86-evoked increases in renal nerve activity and hypotension were attenuated by pretreatment (i.c.v.) with SB204741 (300 nmol kg(-1); a 5-HT(2B) receptor antagonist) but not by the same dose (i.c.v.) of ketanserin (a 5-HT(2A) receptor antagonist) or RS102221 (a 5-HT(2C) receptor antagonist). "
4.	Hyperglycemia 12/01/2020 - "Treatment with the selective htr2b antagonist SB204741 suppressed the hyperglycemia in either db/db mice or KKAy mice. "
5.	Hyperalgesia 01/01/2020 - "Microinjection of preferential or selective 5-HT2A/C, 5-HT2B and 5-HT2C receptor agonists, (±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI), α-methyl-5-(2-thienylmethoxy)-1H-Indole-3-ethanamine hydrochloride (BW723C86) and 1-(3-Chlorophenyl)-piperazine hydrochloride (m-CPP) into the VLO significantly depressed allodynia induced by SNI, and the inhibitory effect of DOI was blocked or attenuated by selective 5-HT2A/C receptor antagonists ketanserin (+)-tartrate salt (ketanserin) and 5-HT2A receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (M100907); the effects of BW723C86 and m-CPP were antagonized by 5-HT2B receptor antagonists N-(1-Methyl-1H-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea (SB204741) and 5-HT2C receptor antagonist RS102221 hydrochloride hydrate (RS-102221), respectively. "

Related Drugs and Biologics

1.	dironyl (terguride)
2.	Ketanserin
3.	5-HT2C Serotonin Receptor
4.	5-HT2B Serotonin Receptor
5.	5-HT2A Serotonin Receptor (5 HT2A Receptor)
6.	Salts
7.	1- (5- (2- thenyloxy)- 1H- indol- 3- yl)propan- 2- amine
8.	volinanserin
9.	tartaric acid (tartrate)
10.	1-(3-chlorophenyl)piperazine